Blood Pressure and Anticoagulation Reversal in Acute ICH
Mr. K, 72, presents 3 hours after sudden right-sided weakness and aphasia. CT shows an 18 mL left basal ganglia intraparenchymal hemorrhage. BP is 206/108 mmHg, HR 88, GCS 14 (E4 V4 M6), NIHSS 12. He takes apixaban 5 mg twice daily; the last dose was 10 hours ago. CrCl is 42 mL/min, weight 78 kg. He takes no antiplatelet agents. His family asks about "reversing the blood thinner."
1. What BP target and agent would you use, and how would you titrate?
Read the worked answer
For spontaneous ICH with SBP >150 mmHg, target SBP about 140 mmHg (acceptable range 130–150) with smooth, continuous control, generally within 1 hour, while avoiding drops below 130 mmHg.
Use IV nicardipine starting at 5 mg/hr, titrating by 2.5 mg/hr every 5–15 minutes to effect. Labetalol is an alternative if there is no contraindication. Avoid nitroprusside because of ICP elevation and cyanide risk. Monitor BP every 5–15 minutes during titration, with an arterial line if available, and reassess neurologically for expansion.
2. What reversal strategy is appropriate for apixaban, given the timing and renal function? What if the specific agent is unavailable?
Read the worked answer
For apixaban taken within 18 hours, andexanet alfa is the specific reversal agent. With a 5 mg dose and last dose 8–18 hours ago, the low-dose regimen is appropriate: 400 mg IV bolus at 4 mg/min for 2 hours (renal function does not change the labeled dose).
If andexanet is unavailable, give 4-factor PCC 50 units/kg (about 3,900 units) based on guideline recommendations, and consider tranexamic acid per protocol. Do not use FFP as first-line. Send a calibrated anti-Xa level if available, but do not delay reversal for results. Hold apixaban, check CBC/coags, type and screen, and monitor for expansion.
3. How would you counsel the family about restarting anticoagulation, and what safety issues matter?
Read the worked answer
Anticoagulation is held acutely and generally restarted 2–4 weeks after ICH, individualized by bleeding risk, infarct risk, and imaging. Restarting too early increases rebleeding; delaying too long increases thromboembolism. Shared decision-making with neurology, cardiology, and the family is essential.
Apixaban 5 mg twice daily remains appropriate: dose reduction requires two of three criteria (age ≥80, weight ≤60 kg, CrCl ≤30), and he meets none (age 72, 78 kg, CrCl 42). Address fall risk, strict BP control, renal monitoring, and adherence. Teach signs of recurrent bleeding and when to seek emergency care.